Synthetic agonists of TLR9
US7884197B2 · kind B2 · utility
10Cited by
0References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 12, 2007 |
| Grant date | Feb 8, 2011 |
| Priority date | — |
| Expiry date | Dec 12, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/336
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides novel oligonucleotide-based compounds that individually provide distinct immune response profiles through their interactions as agonists with TLR9. The TLR9 agonists according to the invention are characterized by specific and unique chemical modifications, which provide their distinctive immune response activation profiles.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.